JP2024545420A5 - - Google Patents
Info
- Publication number
- JP2024545420A5 JP2024545420A5 JP2024532444A JP2024532444A JP2024545420A5 JP 2024545420 A5 JP2024545420 A5 JP 2024545420A5 JP 2024532444 A JP2024532444 A JP 2024532444A JP 2024532444 A JP2024532444 A JP 2024532444A JP 2024545420 A5 JP2024545420 A5 JP 2024545420A5
- Authority
- JP
- Japan
- Prior art keywords
- deletion
- amino acid
- cov
- glycoprotein
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284497P | 2021-11-30 | 2021-11-30 | |
| US63/284,497 | 2021-11-30 | ||
| US202163292120P | 2021-12-21 | 2021-12-21 | |
| US63/292,120 | 2021-12-21 | ||
| US202163293519P | 2021-12-23 | 2021-12-23 | |
| US63/293,519 | 2021-12-23 | ||
| US202263332530P | 2022-04-19 | 2022-04-19 | |
| US63/332,530 | 2022-04-19 | ||
| US202263367678P | 2022-07-05 | 2022-07-05 | |
| US63/367,678 | 2022-07-05 | ||
| PCT/US2022/080700 WO2023102448A2 (en) | 2021-11-30 | 2022-11-30 | Coronavirus vaccine formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545420A JP2024545420A (ja) | 2024-12-06 |
| JP2024545420A5 true JP2024545420A5 (cg-RX-API-DMAC7.html) | 2025-11-13 |
Family
ID=86613115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532444A Pending JP2024545420A (ja) | 2021-11-30 | 2022-11-30 | コロナウイルスワクチン製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250025549A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4440613A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024545420A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240125935A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022399829A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3241118A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313254A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024006589A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202332685A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023102448A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CN116622651A (zh) * | 2022-03-25 | 2023-08-22 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 缺失Furin酶切位点的新冠病毒株及其应用 |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024089638A1 (en) * | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| US20250144200A1 (en) | 2023-11-06 | 2025-05-08 | Novavax, Inc. | Intranasal immunogenic compositions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021214064A1 (en) * | 2020-01-27 | 2022-08-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| WO2021154763A1 (en) * | 2020-01-28 | 2021-08-05 | Modernatx, Inc. | Coronavirus rna vaccines |
| TW202204380A (zh) * | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗 |
| JP2025500433A (ja) * | 2021-12-23 | 2025-01-09 | ノババックス,インコーポレイテッド | 抗SARS-CoV-2スパイク(S)抗体およびCOVID-19の処置におけるそれらの使用 |
| IL318555A (en) * | 2022-07-26 | 2025-03-01 | Novavax Inc | ACE2 Blockade Test to Assess the Immunogenicity of Vaccines |
| US20260028644A1 (en) * | 2022-07-26 | 2026-01-29 | Novavax, Inc. | Pseudovirus based neutralization assay for evaluating vaccine immunogenicity |
-
2022
- 2022-11-30 KR KR1020247021797A patent/KR20240125935A/ko active Pending
- 2022-11-30 EP EP22902377.5A patent/EP4440613A4/en active Pending
- 2022-11-30 CA CA3241118A patent/CA3241118A1/en active Pending
- 2022-11-30 MX MX2024006589A patent/MX2024006589A/es unknown
- 2022-11-30 US US18/715,010 patent/US20250025549A1/en active Pending
- 2022-11-30 AU AU2022399829A patent/AU2022399829A1/en active Pending
- 2022-11-30 IL IL313254A patent/IL313254A/en unknown
- 2022-11-30 WO PCT/US2022/080700 patent/WO2023102448A2/en not_active Ceased
- 2022-11-30 TW TW111145944A patent/TW202332685A/zh unknown
- 2022-11-30 JP JP2024532444A patent/JP2024545420A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9951113B2 (en) | Lectin compositions and methods for modulating an immune response to an antigen | |
| JP2026026092A5 (cg-RX-API-DMAC7.html) | ||
| JP2023512648A5 (cg-RX-API-DMAC7.html) | ||
| JP2010500399A5 (cg-RX-API-DMAC7.html) | ||
| CN116655748B (zh) | 一种截短型水痘-带状疱疹病毒gE蛋白及其应用 | |
| JP2024511412A5 (cg-RX-API-DMAC7.html) | ||
| JP2024516309A5 (cg-RX-API-DMAC7.html) | ||
| CA2496384C (en) | Lectin compositions and methods for modulating an immune response to an antigen | |
| US7629440B2 (en) | Lectin compositions and methods for modulating an immune response to an antigen | |
| US20080063649A1 (en) | Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response | |
| RU2018111760A (ru) | Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью | |
| JP6676661B2 (ja) | ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物 | |
| WO2019092002A1 (en) | Pharmaceutical compositions for treatment or prevention of viral infections | |
| Chiou et al. | Effect of cecropin B and a synthetic analogue on propagation of fish viruses in vitro | |
| CN113226364A (zh) | 组合物和方法 | |
| JP2023542297A5 (cg-RX-API-DMAC7.html) | ||
| JP2024523329A5 (cg-RX-API-DMAC7.html) | ||
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| Wang et al. | Embryonic stem cells attenuate viral myocarditis in murine model | |
| JPWO2016059911A1 (ja) | マラリアワクチン | |
| KR20120129893A (ko) | 고령자에 보호 면역을 제공하기 위한 방법 및 조성물 | |
| CA2183260A1 (en) | Prolactin as a vaccine adjuvant | |
| JP2024511356A5 (cg-RX-API-DMAC7.html) | ||
| JP2024539520A5 (cg-RX-API-DMAC7.html) | ||
| CN116390751A (zh) | 多价β-冠状病毒疫苗、其设计和用途 |